Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
about
Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases.CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan InteractionsThe role of chemokines in Guillain-Barré syndrome.Anti-HIV drug development through computational methods.Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study.Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.A diagnostic HIV-1 tropism system based on sequence relatedness.Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in ratsVirologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses.Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissuesNon-natural peptide triazole antagonists of HIV-1 envelope gp120.Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.Physiology and pharmacology of plerixafor.Chemokine receptor modeling: an interdisciplinary approach to drug design.Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination.Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.Rational CCL5 mutagenesis integration in a lactobacilli platform generates extremely potent HIV-1 blockers.A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.HIV-1 and the macrophageA Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
P2860
Q30427403-8C85CF2A-3B00-46AD-BA1F-41CD72562A00Q30848125-AB5354FC-27A7-4DB7-A796-437D1E5823CAQ33624382-5C869632-D6C5-4F16-BCCC-D9CA81C9E73DQ33803979-6DFABDED-C420-4E82-A4FA-3FF26530C99EQ34477067-1689E8DD-6A95-457C-B1E2-3FCAD9DF0949Q34801630-2CFB6091-A810-42C2-9A93-A5EBD9B520FCQ34983107-B805B7F1-1492-41CA-94D9-ABAB3EFE5BE2Q35036778-9AE9CBA1-8354-4E94-85F0-D009B24DA552Q35057326-2E97A2D5-64D5-47A1-AE04-17FF330E7C22Q35531310-160372E9-279C-433D-A9FD-96251D326A83Q35953203-393C51AA-FD1A-4D1B-B61D-716A1846819EQ36306935-87302708-8042-49BB-ADCD-B8DD3F4ECEF3Q37123335-57B7DA0F-C04A-495D-BF05-A25DB71ECAC7Q37260033-83DA2C3C-F2BF-4C97-A9BC-AD1BC1E545BAQ37637067-05B778DE-6A8D-4C6D-80B2-A100E8CB9819Q37979697-AFC56E59-C847-4A1E-B835-486BC9E26B06Q38056759-723C21F2-EE0E-41EF-B66D-9AAFA7818253Q38157897-0A7B380E-12E0-4FF0-9EA3-29479611DB67Q38172960-DD989DE3-DEE0-4DE3-A883-3D70368E9F3EQ38650120-F0FAA38C-4C3C-45AC-AB39-3B6A1EF4EBAFQ39243936-319CC813-5965-494F-A328-F48B97289369Q39471859-637CDCD6-6197-4D02-89FF-04D85FD86948Q39944975-05A23CF5-635D-4E92-A26D-48F715213A43Q41846910-28D42283-295D-46CD-AD6F-C234D590DE40Q47800411-7A433179-27EE-42A0-9F50-E2C0B43E49A7Q54248548-2E5416E0-B273-42CD-B717-CB604C418C53Q55967625-B5466287-2492-46C4-B03B-AF72924EB1ACQ56763230-CCE460C4-7628-4448-B1BC-EA398D1BB75B
P2860
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@en
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@nl
type
label
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@en
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@nl
prefLabel
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@en
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@nl
P1433
P1476
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
@en
P304
P356
10.2165/11203940-000000000-00000
P577
2010-06-01T00:00:00Z
P6179
1011423491